University of Kentucky Medical Center Discharges
State's 1st SynCardia Total Artificial Heart Patient
20-Year-Old Zack Poe Leaves the Hospital to Wait for a Matching Donor Heart at Home
TUCSON, Ariz. – March 21, 2012 – SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that on March 5, University of Kentucky Medical Center (UK) in Lexington discharged its first patient to be implanted with the SynCardia temporary Total Artificial Heart. Zack Poe, 20, is the first patient in the state to leave the hospital to wait for a matching donor heart at home using the Freedom® portable driver to power his Total Artificial Heart.
"The mobility that the Freedom driver allows is a great benefit to patients who receive the SynCardia Total Artificial Heart," said Dr. Jay Zwischenberger, chair of the UK Department of Surgery. "Zack will be able to go home and enjoy his life, rather than waiting months in a hospital room for a donor heart."
Zack's journey began on Jan. 2, 2012, when he went to the doctor for an ulcer and was referred to an emergency room. After being diagnosed with pneumonia, he was given two liters of fluid, which resulted in immediate swelling. Doctors started Zack on medication and performed an ECHO to see what was wrong. The ECHO showed that Zack's ejection fraction -- a measurement of how much blood the heart pumps out to the body during each beat -- was less than 10 percent. In a healthy individual, it is usually 55 to 75%. Zack was referred to UK for consideration of advanced treatment options. About a week and a half after his initial diagnosis, his liver began to fail.
"Apart from his heart failure, Zack is a strong, healthy young man," said Dr. Charles Hoopes, director of the UK Heart and Lung Transplant Program and the Mechanical Cardiac Support Program. "But because of the severity of the heart failure, we felt he was the perfect candidate to receive the Total Artificial Heart while he waits on an appropriate donor heart."
To save Zack's life, UK Medical Center set a record as the fastest hospital to complete all four phases of certification required to implant the Total Artificial Heart, discharging Zack home just 25 days after beginning the certification process.
"The operation went really smoothly. Zack was off the breathing tube the next day and was up and walking around within several days and has had a remarkable recovery," said UK surgeon Dr. Mark Plunkett, chief of Cardiothoracic Surgery and the co-director of the Linda and Jack Gill Heart Institute.
When doctors first told Zack about the Total Artificial Heart, he said he was receptive to the idea because it would keep him healthy enough until he could receive a heart transplant.
"I feel a million times better. Because of the outflow volume, I've been able to walk longer without pain than I have in months," said Zack.
A second UK patient was implanted with the Total Artificial Heart on Feb. 29 and is doing well. Dr. Hoopes said they hope to perform six implants a year, with an ultimate goal of 10 to 12 annually.
The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.